[{"orgOrder":0,"company":"Vyant Bio","sponsor":"OrganoTherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Discovery","graph3":"Vyant Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Vyant Bio \/ OrganoTherapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Vyant Bio \/ OrganoTherapeutics"},{"orgOrder":0,"company":"Vyant Bio","sponsor":"The Loulou Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Vyant Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Vyant Bio \/ The Loulou Foundation","highestDevelopmentStatusID":"3","companyTruncated":"Vyant Bio \/ The Loulou Foundation"},{"orgOrder":0,"company":"Vyant Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Vyant Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Vyant Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Vyant Bio \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Vyant Bio

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BIO Partnering at JPM
                          Not Confirmed
                          BIO Partnering at JPM
                          Not Confirmed

                          Details : Rett syndrome (RTT) is a progressive neurodevelopmental disorder caused by mutations in the X-linked gene MECP2. One of the challenges developing therapeutics for RTT has been the lack of a screening system that recapitulates the underlying human disease...

                          Brand Name : Undisclosed

                          Molecule Type : Undisclosed

                          Upfront Cash : Not Applicable

                          November 16, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          BIO Partnering at JPM
                          Not Confirmed
                          BIO Partnering at JPM
                          Not Confirmed

                          Details : High-throughput functional screening to develop novel therapies for CDKL5-deficiency disorder using human iPSC-derived cortical organoids.CDKL5 stands for cyclin-dependent kinase-like 5, a protein whose gene is located on the X chromosome.

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          October 27, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Discovery Platform

                          Sponsor : The Loulou Foundation

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          BIO Partnering at JPM
                          Not Confirmed
                          BIO Partnering at JPM
                          Not Confirmed

                          Details : The collaboration brings together the respective teams’ expertise in drug discovery using human-derived cells, high-throughput biology and chemistry, and machine learning-based therapeutic design to identify potential PD drugs.

                          Brand Name : Undisclosed

                          Molecule Type : Undisclosed

                          Upfront Cash : Undisclosed

                          March 29, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Neurology

                          Highest Development Status : Discovery

                          Sponsor : OrganoTherapeutics

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank